{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:44:33Z","timestamp":1763037873994,"version":"3.40.5"},"reference-count":33,"publisher":"Index Copernicus","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Otolaryngol Pol"],"published-print":{"date-parts":[[2023,3,14]]},"abstract":"<jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) has a significant impact on the well-being and social functions of the patient. The generalized inflammatory process with the formation of nasal polyps and excess eosinophils in the mucosa of the paranasal sinuses is called type 2 inflammation, which is mediated by Th2 lymphocytes \u2013 cells of the immune system responsible for chronic inflammatory processes. Today, we also know the key pro-inflammatory mediators against which new drugs have been developed, the so-called biological drugs, are produced in cell lines. In this document, we present currently available biologicals approved for the treatment of patients with T2-related chronic rhinosinusitis.<\/jats:p>","DOI":"10.5604\/01.3001.0053.5965","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T09:39:30Z","timestamp":1684229970000},"page":"1-11","source":"Crossref","is-referenced-by-count":5,"title":["Biologicals in the treatment of chronic rhinosinusitis with nasal polyps \u2013 position of the Polish Society of Otorhinolaryngologists \u2013 Head and Neck Surgeons and the PolishSociety of Allergology experts"],"prefix":"10.5604","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-2679","authenticated-orcid":false,"given":"Dariusz","family":"Jurkiewicz","sequence":"first","affiliation":[{"name":"Department of Otolaryngology and Laryngological Oncology with Clinical Department of Cranio-Maxillofacial Surgery, Military Institute of Medicine \u2013 National Research Institute in Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0800-7867","authenticated-orcid":false,"given":"Maciej","family":"Kupczyk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3113-3079","authenticated-orcid":false,"given":"Eliza","family":"Bro\u017cek-M\u0105dry","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-0294","authenticated-orcid":false,"given":"Piotr","family":"Rapiejko","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology and Laryngological Oncology with Clinical Department of Cranio-Maxillofacial Surgery, Military Institute of Medicine \u2013 National Research Institute in Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3689","reference":[{"key":"613225r1","doi-asserted-by":"crossref","unstructured":"Fokkens W.J., Lund V.J., Hopkins C. et al.: European Position Paper on Rhinosinusitisand Nasal Polyps, Rhinology, 2020; 58 (Suppl S29): 1\u2013464. DOI:10.4193\/Rhin20.600.","DOI":"10.4193\/Rhin20.600"},{"key":"613225r2","doi-asserted-by":"crossref","unstructured":"Khan A., Vandeplas G., Huynh T.M.T. et al: The Global Allergy and AsthmaEuropean Network (GALEN rhinosinusitis cohort: a large European cross-sectionalstudy of chronic rhinosinusitis patients with and without nasal polyps.Rhinology, 2019; 57(1): 32\u201342. DOI: 10.4193\/Rhin17.255.","DOI":"10.4193\/Rhin17.255"},{"key":"613225r3","unstructured":"Rond\u00f3n C., D\u00e1vila I., Navarro Pulido A.M. et al.: Rhinoconjunctivitis Committee;Spanish Society of Allergy and Clinical Immunology. Clinical Managementand Use of Health Care Resources in the Treatment of Nasal Polyposisin Spanish Allergy Centers: The POLAR Study. J Investig Allergol Clin Immunol.,2015; 25(4): 276\u2013282.."},{"key":"613225r4","doi-asserted-by":"crossref","unstructured":"Benjamin M.R., Stevens W.W., Li N. et al.: Clinical Characteristics of Patientswith Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting.J Allergy Clin Immunol Pract., 2019; 7(3): 1010\u20131016. DOI: 10.1016\/j.jaip.2018.10.014.","DOI":"10.1016\/j.jaip.2018.10.014"},{"key":"613225r5","doi-asserted-by":"crossref","unstructured":"Promsopa C., Kansara S., Citardi M.J. et al.: Prevalence of confirmed asthmavaries in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol., 2016; 6(4):373\u2013377. DOI: 10.1002\/alr.21674.","DOI":"10.1002\/alr.21674"},{"key":"613225r6","doi-asserted-by":"crossref","unstructured":"Stevens W.W., Peters A.T., Hirsch A.G. et al.: Clinical Characteristics of Patientswith Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin--Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract., 2017; 5(4):1061\u20131070.e3. DOI: 10.1016\/j.jaip.2016.12.027.","DOI":"10.1016\/j.jaip.2016.12.027"},{"key":"613225r7","doi-asserted-by":"crossref","unstructured":"Rajan J.P., Wineinger N.E., Stevenson D.D., White A.A.: Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysisof the literature. J Allergy Clin Immunol., 2015; 135(3): 676\u2013681.e1. DOI:10.1016\/j.jaci.2014.08.020.","DOI":"10.1016\/j.jaci.2014.08.020"},{"key":"613225r8","doi-asserted-by":"crossref","unstructured":"Xu X., Reitsma S., Wang Y., Fokkens W.J.: Updates in biologic therapy for chronicrhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease.Allergy., 2022; 77(12): 3593\u20133605. DOI: 10.1111\/all.15507.","DOI":"10.1111\/all.15507"},{"key":"613225r9","doi-asserted-by":"crossref","unstructured":"Gandhi N.A., Pirozzi G., Graham N.M.H.: Commonality of the IL-4\/IL-13 pathwayin atopic diseases. Expert Rev Clin Immunol, 2017; 13: 425\u201343. DOI:10.1080\/1744666X.2017.1298443.","DOI":"10.1080\/1744666X.2017.1298443"},{"key":"613225r10","doi-asserted-by":"crossref","unstructured":"Tsabouri S., Ntritsos G., Koskeridis F. et al.: Omalizumab for the treatmentof allergic rhinitis: a systematic review and meta-analysis. Rhinology., 2021;59(6): 501\u2013510. DOI: 10.4193\/Rhin21.159.","DOI":"10.4193\/Rhin21.159"},{"key":"613225r11","doi-asserted-by":"crossref","unstructured":"Gevaert P., Omachi T.A., Corren J. et al.: Efficacy and safety of omalizumab innasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol., 2020;146(3): 595\u2013605. DOI: 10.1016\/j.jaci.2020.05.032.","DOI":"10.1016\/j.jaci.2020.05.032"},{"key":"613225r12","doi-asserted-by":"crossref","unstructured":"Gevaert P., Saenz R., Corren J. et al.: Long-term efficacy and safety of omalizumabfor nasal polyposis in an open-label extension study. J Allergy Clin Immunol.,2022; 149(3): 957\u2013965.e3. DOI: 10.1016\/j.jaci.2021.07.045.","DOI":"10.1016\/j.jaci.2021.07.045"},{"key":"613225r13","doi-asserted-by":"crossref","unstructured":"Bachert C., Han J.K., Desrosiers M. et al. Efficacy and safety of dupilumab inpatients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NPSINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised,double-blind, placebo-controlled, paralel -group phase 3 trials. Lancet.,2019; 394: 1638\u20131650. DOI: 10.1016\/S0140-6736(19)31881-1.","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"613225r14","doi-asserted-by":"crossref","unstructured":"Fujieda S., Matsune S., Takeno S. et al.: Dupilumab efficacy in chronic rhinosinusitiswith nasal polyps from SINUS-52 is unaffected by eosinophilic status.Allergy., 2022; 77(1): 186\u2013196. DOI: 10.1111\/all.14906.","DOI":"10.1111\/all.14906"},{"key":"613225r15","doi-asserted-by":"crossref","unstructured":"Bachert C., Hellings P.W., Mullol J. et al.: Dupilumab improves health- relatedquality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy.,2020; 75(1): 148\u2013157. DOI: 10.1111\/all.13984.","DOI":"10.1111\/all.13984"},{"key":"613225r16","doi-asserted-by":"crossref","unstructured":"Mullol J., Laidlaw T.M., Bachert C. et al.: Efficacy and safety of dupilumab inpatients with uncontrolled severe chronic rhinosinusitis with nasal polyps anda clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlledphase 3 trials. Allergy., 2022; 77(4): 1231\u20131244. DOI: 10.1111\/all.15067.","DOI":"10.1111\/all.15067"},{"key":"613225r17","doi-asserted-by":"crossref","unstructured":"Wangberg H., Spierling Bagsic S.R., Osuna L., White A.A.: Appraisal of theReal-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated RespiratoryDisease. J Allergy Clin Immunol Pract., 2022; 10(2): 478\u2013484.e3. DOI:10.1016\/j.jaip.2021.09.030.","DOI":"10.1016\/j.jaip.2021.09.030"},{"key":"613225r18","doi-asserted-by":"crossref","unstructured":"Kariyawasam H.H., Chandrasekharan D.P., Jacques T. et al.: Biologic treatmentfor severe chronic rhinosinusitis with nasal polyps: a systematic reviewand meta-analysis. Rhinology, 2023; 61(2): 98\u2013107. DOI: 10.4193\/Rhin22.412.","DOI":"10.4193\/Rhin22.412"},{"key":"613225r19","doi-asserted-by":"crossref","unstructured":"Han J.K., Bachert C., Fokkens W. et al.: SYNAPSE study investigators. Mepolizumabfor chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised,double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med., 2021;9(10): 1141\u20131153. DOI: 10.1016\/S2213-2600(21)00097-7.","DOI":"10.1016\/S2213-2600(21)00097-7"},{"key":"613225r20","doi-asserted-by":"crossref","unstructured":"Bachert C., Sousa A.R., Han J.K. et al.: Mepolizumab for chronic rhinosinusitiswith nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.J Allergy Clin Immunol., 2022; 149(5): 1711\u20131721.e6. DOI: 10.1016\/j.jaci.2021.10.040.","DOI":"10.1016\/j.jaci.2021.10.040"},{"key":"613225r21","doi-asserted-by":"crossref","unstructured":"Detoraki A., Tremante E., D\u2019Amato M. et al.: Mepolizumab improves sino-nasalsymptoms and asthma control in severe eosinophilic asthma patients withchronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther AdvRespir Dis. 2021;15:17534666211009398. DOI: 10.1177\/17534666211009398.","DOI":"10.1177\/17534666211009398"},{"key":"613225r22","doi-asserted-by":"crossref","unstructured":"Chan R., RuiWen Kuo C., Lipworth B.: Disconnect between effects of mepolizumabon severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps. J AllergyClin Immunol Pract., 2020; 8(5): 1714\u20131716. DOI: 10.1016\/j.jaip.2020.01.009.","DOI":"10.1016\/j.jaip.2020.01.009"},{"key":"613225r23","doi-asserted-by":"crossref","unstructured":"Laidlaw T.M., Prussin C., Panettieri R.A. et al.: Dexpramipexole depletes bloodand tissue eosinophils in nasal polyps with no change in polyp size. Laryngoscope.,2019; 129(2): E61\u2013E66. DOI: 10.1002\/lary.27564.","DOI":"10.1002\/lary.27564"},{"key":"613225r24","doi-asserted-by":"crossref","unstructured":"Bachert C., Han J.K., Desrosiers M.Y. et al.: Efficacy and safety of benralizumabin chronic rhinosinusitis with nasal polyps: A randomized, placebo--controlled trial. J Allergy Clin Immunol., 2022; 149(4): 1309\u20131317.e12. DOI:10.1016\/j.jaci.2021.08.030.","DOI":"10.1016\/j.jaci.2021.08.030"},{"key":"613225r25","doi-asserted-by":"crossref","unstructured":"Harrison T.W., Chanez P., Menzella F. et al.: ANDHI study investigators. Onsetof effect and impact on health-related quality of life, exacerbation rate,lung function, and nasal polyposis symptoms for patients with severe eosinophilicasthma treated with benralizumab (ANDHI): a randomised, controlled,phase 3b trial. Lancet Respir Med., 2021; 9(3): 260\u2013274. DOI: 10.1016\/S2213-2600(20)30414-8.","DOI":"10.1016\/S2213-2600(20)30414-8"},{"key":"613225r26","doi-asserted-by":"crossref","unstructured":"Canonica G.W., Harrison T.W., Chanez P. et al.: Benralizumab improves symptomsof patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.Allergy., 2022; 77(1): 150\u2013161. DOI: 10.1111\/all.14902.","DOI":"10.1111\/all.14902"},{"key":"613225r27","doi-asserted-by":"crossref","unstructured":"Bachert C., Sousa A.R., Lund V.J. et al. Reduced need for surgery in severe nasalpolyposis with mepolizumab: Randomized trial. J Allergy Clin Immunol.2017;140:1024-31.e14. DOI: 10.1016\/j.jaci.2017.05.044.","DOI":"10.1016\/j.jaci.2017.05.044"},{"key":"613225r28","doi-asserted-by":"crossref","unstructured":"Rot P., Rapiejko P., Jurkiewicz D.: Intranasal steroid therapy \u2013 EPOS 2020; OtolaryngolPol, 2020; 74(3): 41\u201349. DOI: 10.5604\/01.3001.0014.2449.","DOI":"10.5604\/01.3001.0014.2449"},{"key":"613225r29","doi-asserted-by":"crossref","unstructured":"Zhang N., Holtappels G., Gevaert P. et al. Mucosal tissue polyclonal IgE isfunctional in response to allergen and SEB. Allergy., 2011; 66: 141\u2013148. DOI:10.1111\/j.1398-9995.2010.02448.x.","DOI":"10.1111\/j.1398-9995.2010.02448.x"},{"key":"613225r30","doi-asserted-by":"crossref","unstructured":"Gevaert P., Calus L., Van Zele T. et al. Omalizumab is effective in allergic andnonallergic patients with nasal polyps and asthma. The J Allergy Clin Immunol.,2013; 131: 110\u2013116.e1. DOI: 10.1016\/j.jaci.2012.07.047.1","DOI":"10.1016\/j.jaci.2012.07.047"},{"key":"613225r31","doi-asserted-by":"crossref","unstructured":"Pinto J.M., Mehta N., DiTineo M. et al.: A randomized, double-blind, placebo-controlled trial of anti-IgE for chroni\u0107 rhinosinusitis. Rhinology, 2010; 48:318\u2013324. DOI: 10.4193\/Rhino09.144.","DOI":"10.4193\/Rhin09.144"},{"key":"613225r32","doi-asserted-by":"crossref","unstructured":"Busse W.W., Viswanathan R.: Wkat has been learned by cytokine targetingof asthma?. J All Clin Immunol., 2022; 150: 235\u2013249. DOI: 10.1016\/j.jaci.2022.06.010.","DOI":"10.1016\/j.jaci.2022.06.010"},{"key":"613225r33","doi-asserted-by":"crossref","unstructured":"Rik J.L. van der Lans, Hopkins C. et al.: Biologicals and Endoscopic Sinus Surgeryfor Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: AnEconomic Perspective. J Allergy Clin Immunol Pract., 2022; 10: 1454\u20131461.","DOI":"10.1016\/j.jaip.2022.02.017"}],"container-title":["Otolaryngologia Polska"],"original-title":[],"link":[{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0053.5965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0053.5965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T13:03:22Z","timestamp":1729429402000},"score":1,"resource":{"primary":{"URL":"https:\/\/otolaryngologypl.com\/gicid\/01.3001.0053.5965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3,14]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0053.5965","relation":{},"ISSN":["0030-6657","2300-8423"],"issn-type":[{"type":"print","value":"0030-6657"},{"type":"electronic","value":"2300-8423"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}